Business Context and Reporting Period
Company: NANOVIRICIDES, INC.
Filing Type: Form 8-K (Current Report)
Date of Report: September 16, 2011
Event: Extension of warrant expiration dates and disclosure of unregistered equity sales.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The report focuses exclusively on a corporate action regarding equity instruments.
Material Changes
On September 16, 2011, the Company extended the expiration date of warrants to purchase an aggregate of 3,372,700 shares of common stock to September 30, 2012. No other terms of the warrants were amended. The warrant breakdown is as follows:
- 1,500,000 warrants: Exercise price of $1.00 per share.
- 1,643,000 warrants: Exercise price of $2.00 per share.
- 240,000 warrants: Issued to Scientific Advisory Board Members with exercise prices ranging from $0.70 to $1.56 per share.
Guidance, Outlook, and Risks
Regulatory Status: The securities were offered and sold in reliance on exemptions from registration under Section 4(2) of the Securities Act and Rule 506. The Company represented that investors were "accredited investors" with access to adequate information regarding the Company's operations and financial condition.
Restrictions: The securities are deemed restricted securities and bear legends to that effect. They may not be resold or offered in the United States without registration or an applicable exemption.
Investor Verification Checklist
- Verify the total number of outstanding warrants (3,372,700) and the new expiration date (September 30, 2012).
- Confirm the specific exercise prices applicable to different warrant tranches ($1.00, $2.00, and $0.70-$1.56).
- Review the Company's current cash position to assess the likelihood of warrant exercise given the lack of revenue data in this filing.
- Check for any subsequent filings regarding the resale restrictions or registration of these securities.